Antioxidant therapies have proved to have some utility when used as adjuvants in MS treatment, with endogenous Nrf2 being an important treatment target for the induction of endogenous antioxidants (Kappos et al., 2010; Lim et al., 2014). Here, NFE2L2 is linked to myeloid sarcoma.